PAPP-A: a promising therapeutic target for healthy longevity
- PMID: 28035757
- PMCID: PMC5334524
- DOI: 10.1111/acel.12564
PAPP-A: a promising therapeutic target for healthy longevity
Abstract
Pregnancy-associated plasma protein-A (PAPP-A) is a proteolytic enzyme that was discovered to increase local insulin-like growth factor (IGF) availability for receptor activation through cleavage of inhibitory IGF binding proteins (IGFBPs). Reduced IGF signaling has been associated with increased lifespan and healthspan. Therefore, inhibition of PAPP-A represents a novel approach to indirectly decrease the availability of bioactive IGF. Here, we will review data in support of PAPP-A as a therapeutic target to promote healthy longevity.
Keywords: IGF; PAPP-A; aging.
© 2016 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
Figures
References
-
- Bartke A (2003) Can growth hormone (GH) accelerate aging? Evidence from GH‐transgenic mice. Neuroendocrinology 78, 210–216. - PubMed
-
- Bayes‐Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Holmes DR Jr, Virmani R, Oxvig C, Schwartz RS (2001) Pregnancy‐associated plasma protein‐A and diagnosis of acute coronary syndromes. N. Engl. J. Med. 345, 1022–1029. - PubMed
-
- Boldt HB, Conover CA (2011) Overexpression of pregnancy‐associated plasma protein‐A in ovarian cancer cells promotes tumor growth in vivo . Endocrinology 152, 1470–1478. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
